无排卵程序化冻融胚胎移植周期中胚胎移植日地屈孕酮和20α-二氢地屈孕酮血浆水平与临床结局:一项前瞻性队列研究
该前瞻性队列研究纳入217例接受程序化冻融胚胎移植的妇女,口服雌二醇和地屈孕酮10 mg每日三次,在移植日测定地屈孕酮及其代谢物20α-二氢地屈孕酮血浆浓度。地屈孕酮和20α-二氢地屈孕酮水平在服药第3天达稳态,两者强相关,个体间和个体内变异大;水平处于最低四分位的患者持续妊娠率显著降低。
要点
- 口服地屈孕酮10 mg每日三次,血浆地屈孕酮和20α-二氢地屈孕酮水平在服药第3天达稳态。
- 移植日地屈孕酮或20α-二氢地屈孕酮水平≤第25百分位者持续妊娠率显著低于>第25百分位者。
- 地屈孕酮和20α-二氢地屈孕酮水平强相关,但个体间和个体内变异大,部分人群10 mg每日三次可能为次优剂量。
核心结论
- 地屈孕酮和20α-二氢地屈孕酮血浆水平在服药第3天达稳态,两者强相关,个体间和个体内变异大;移植日地屈孕酮或20α-二氢地屈孕酮水平处于最低四分位的患者持续妊娠机会降低。
研究设计与样本
- 前瞻性临床队列研究(2018年5月至2020年11月,NCT03507673),在大学体外受精中心进行,纳入217例接受程序化冻融胚胎移植的妇女,口服雌二醇2 mg每日三次,黄体支持为口服地屈孕酮10 mg每日三次。
- 主要纳入标准为雌二醇用药第12-15天无排卵卵泡且血清孕酮低;移植日采集血清和血浆样本,-80°C保存后用液相色谱-串联质谱法(LC-MS/MS)分析。
- 56例患者在同一方案中进行了两个或以上冻融胚胎移植周期。
主要发现
- 排除‘逃逸排卵’患者(n=14,6%)和无LC-MS/MS分析结果患者(n=5)后,分析卵裂期移植观察41例次和囊胚移植观察157例次。
- 移植日(第2或3天)地屈孕酮和20α-二氢地屈孕酮血浆水平中位数(四分位数)分别为1.36 ng/ml(0.738至2.17 ng/ml)和34.0 ng/ml(19.85至51.65 ng/ml);第5天分别为1.04 ng/ml(0.707至1.62 ng/ml)和30.0 ng/ml(20.8至43.3 ng/ml)。
- 20α-二氢地屈孕酮水平与体重和BMI极弱相关(R²<0.05),地屈孕酮水平与体重相关但与BMI无关;地屈孕酮和20α-二氢地屈孕酮水平强相关(第2/3天相关系数0.936,第5天0.892)。
- 移植日地屈孕酮和20α-二氢地屈孕酮水平的第25百分位分别为0.71 ng/ml和20.675 ng/ml。
- 持续妊娠率在地屈孕酮或20α-二氢地屈孕酮水平≤第25百分位者显著降低:地屈孕酮≤第25百分位3/49(6%)vs >第25百分位42/149(28%),未调整差值-22%(CI:-31%至-10%);20α-二氢地屈孕酮≤第25百分位4/49(8%)vs >第25百分位41/149(27%),未调整差值-19%(CI:-29%至-7%);调整后差值-22%,95%CI:-32至-12,P<0.0001。
关键数值与推荐
- 持续妊娠定义为>第10孕周有存活妊娠。
- 地屈孕酮和20α-二氢地屈孕酮水平按移植日分别以第25百分位(≤25th vs >25th)分层比较持续妊娠率。
临床怎么用
- 作者认为,在人工冻融胚胎移植周期中每日10 mg地屈孕酮(每日三次)对部分人群可能是次优剂量。
- 作者认为,地屈孕酮或20α-二氢地屈孕酮水平测量可在未来研究中互换使用。
- 作者建议,口服地屈孕酮的药代动力学及相关生殖药效学需进一步研究。
局限性
- 地屈孕酮水平的个体间和个体内变异部分可归因于末次10 mg地屈孕酮摄入与采血之间的时间差异以及同时进食,本研究均未登记。
- 90%的受试者为欧洲白种人,地屈孕酮/20α-二氢地屈孕酮血药浓度应在其他和更大的人群中重复验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the plasma concentrations of dydrogesterone (DYD) and its metabolite, 20α-dihydrodydrogesterone (DHD), measured on day of embryo transfer (ET) in programmed anovulatory frozen embryo transfer (FET) cycles using 10 mg per os ter-in-die (tid) oral DYD, and what is the association of DYD and DHD levels with ongoing pregnancy rate? SUMMARY ANSWER: DYD and DHD plasma levels reach steady state by Day 3 of intake, are strongly correlated and vary considerably between and within individual subjects, women in the lowest quarter of DYD or DHD levels on day of FET have a reduced chance of an ongoing pregnancy. WHAT IS KNOWN ALREADY: DYD is an oral, systemic alternative to vaginal progesterone for luteal phase support. The DYD and DHD level necessary to sustain implantation, when no endogenous progesterone is present, remains unknown. While DYD is widely used in fresh IVF cycles, circulating concentrations of DYD and DHD and inter- and intraindividual variation of plasma levels versus successful treatment have never been explored as measurement of DYD and DHD is currently only feasible by high-sensitivity chromatographic techniques such as liquid chromatography/tandem mass spectroscopy (LC-MS/MS). STUDY DESIGN, SIZE, DURATION: Prospective, clinical cohort study (May 2018-November 2020) (NCT03507673); university IVF-center; women (n = 217) undergoing a programmed FET cycle with 2 mg oral estradiol (tid) and, for luteal support, 10 mg oral DYD (tid); main inclusion criteria: absence of ovulatory follicle and low serum progesterone on Days 12-15 of estradiol intake; serum and plasma samples were taken on day of FET and stored at -80°C for later analysis by LC-MS/MS; in 56 patients, two or more FET cycles in the same protocol were performed. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women undergoing FET on Day 2 or Day 3 (D2, D3, cleavage) or Day 5 (D5, blastocyst) of embryonic development had blood sampling on the 3rd, 4th or 6th day of 10 mg (tid) DYD oral intake, respectively. The patient population was stratified by DYD and DHD plasma levels by percentiles (≤25th versus >25th) separately by day of ET. Ongoing pregnancy rates (a viable pregnancy at >10th gestational week) were compared between ≤25th percentile versus >25th percentile for DYD and DHD levels (adjusted for day of ET). Known predictors of outcome were screened for their effects in addition to DYD, while DYD was considered as log-concentration or dichotomized at the lower quartile. Repeated cycles were analyzed assuming some correlation between them for a given individual, namely by generalized estimating equations for prediction and generalized mixed models for an estimate of the variance component. MAIN RESULTS AND THE ROLE OF CHANCE: After exclusion of patients with 'escape ovulation' (n = 14, 6%), detected by the presence of progesterone in serum on day of ET, and patients with no results from LC-MS/MS analysis (n = 5), n = 41 observations for cleavage stage ETs and n = 157 for blastocyst transfers were analyzed. Median (quartiles) of plasma levels of DYD and DHD were 1.36 ng/ml (0.738 to 2.17 ng/ml) and 34.0 ng/ml (19.85 to 51.65 ng/ml) on Day 2 or 3 and 1.04 ng/ml (0.707 to 1.62 ng/ml) and 30.0 ng/ml (20.8 to 43.3 ng/ml) on Day 5, respectively, suggesting that steady-state is reached already on Day 3 of intake. DHD plasma levels very weakly associated with body weight and BMI (R2 < 0.05), DYD levels with body weight, but not BMI. Levels of DYD and DHD were strongly correlated (correlation coefficients 0.936 for D2/3 and 0.892 for D5, respectively). The 25th percentile of DYD and DHD levels were 0.71 ng/ml and 20.675 ng/ml on day of ET. The ongoing pregnancy rate was significantly reduced in patients in the lower quarter of DYD or DHD levels: ≤25th percentile DYD or DHD 3/49 (6%) and 4/49 (8%) versus >25th percentile DYD or DHD 42/149 (28%) and 41/149 (27%) (unadjusted difference -22% (CI: -31% to -10%) and -19% (CI: -29% to -7%), adjusted difference -22%, 95% CI: -32 to -12, P < 0.0001). LIMITATIONS, REASONS FOR CAUTION: Some inter- and intraindividual variations in DYD levels could be attributed to differences in time between last 10 mg DYD intake and blood sampling, as well as concomitant food intake, neither of which were registered in this study. Ninety percent of subjects were European-Caucasian and DYD/DHD blood concentrations should be replicated in other and larger populations. WIDER IMPLICATIONS OF THE FINDINGS: Daily 10 mg DYD (tid) in an artificial FET cycle is potentially a suboptimal dose for a proportion of the population. Measurement of DYD or DHD levels could be used interchangeably for future studies. The pharmacokinetics of oral DYD and associated reproductive pharmacodynamics need further study. STUDY FUNDING/COMPETING INTEREST(S): The trial was financed by university funds, except for the cost for plasma and serum sample handling, storage and shipment, as well as the liquid chromatography-mass spectrometry (LC-MS/MS) analysis of DYD, DHD and progesterone, which was financially supported by Abbott Products Operations AG (Allschwil, Switzerland). Abbott Products Operations AG had no influence on the study protocol, study conduct, data analysis or data interpretation. K.N. has received honoraria and/or non-financial support (e.g. travel cost compensation) from Ferring, Gedeon-Richter, Merck and MSD. A.M. has no competing interests. R.V. has no competing interests. M.D. has received honoraria and/or non-financial support from Ferring and Merck. A.S.-M. has no competing interests. T.K.E. has received honoraria and/or non-financial support from Roche, Novartis, Pfizer, Aristo Pharma, Merck. G.G. has received honoraria and/or non-financial support (e.g. travel cost compensation) from Abbott, Ferring, Gedeon Richter, Guerbet, Merck, Organon, MSD, ObsEva, PregLem, ReprodWissen GmbH, Vifor and Cooper. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT03507673.
引用
- Neumann K, Masuch A, Vonthein R, et al. Dydrogesterone and 20α-dihydrodydrogesterone plasma levels on day of embryo transfer and clinical outcome in an anovulatory programmed frozen-thawed embryo transfer cycle: a prospective cohort study. Hum Reprod. 2022. PMID: 35323905. doi:10.1093/humrep/deac045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。